The fact that NAT10 plays a role in distinguishing new-onset AS from HC, RA + SLE and NAT10 correlates with disease activity raises the possibility that NAT10 might be utilized as a diagnostic, prognostic and therapeutic target for AS. This evidence concerns the gene NAT10 and systemic lupus erythematosus.